|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:associated_with
|
improved quality of life
reduced risk of liver cancer
|
|
gptkbp:available_in
|
gptkb:various_countries
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:can_be_combined_with
|
gptkb:sofosbuvir
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:clinical_use
|
chronic hepatitis C
|
|
gptkbp:coadministered_with
|
gptkb:peginterferon
gptkb:ribavirin
|
|
gptkbp:contraindication
|
severe liver disease
certain HIV medications
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:drug_interactions
|
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:amiodarone
gptkb:rifampin
|
|
gptkbp:duration
|
12 weeks
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ledipasvir
|
|
gptkbp:invention
|
2028
|
|
gptkbp:is_monitored_by
|
liver function tests
|
|
gptkbp:lifespan
|
approximately 47 hours
|
|
gptkbp:marketed_as
|
gptkb:Harvoni
|
|
gptkbp:mechanism_of_action
|
inhibits NS5 A protein
|
|
gptkbp:metabolism
|
primarily hepatic
|
|
gptkbp:pharmacokinetics
|
high bioavailability
|
|
gptkbp:price
|
high
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research_focus
|
long-term outcomes
new combinations
resistance testing
treatment of co-infections
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:suitable_for
|
pregnant women
breastfeeding women
|
|
gptkbp:target_audience
|
adults
pediatric patients
|
|
gptkbp:treatment
|
over 90% cure rate
|
|
gptkbp:type_of_care
|
important for treatment success
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:used_for
|
treatment of hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:virus
|
|
gptkbp:bfsLayer
|
4
|